The extradomain A of fibronectin enhances the efficacy of lipopolysaccharide defective Salmonella bacterins as vaccines in mice by San Román, Beatriz et al.
VETERINARY RESEARCH
Román et al. Veterinary Research 2012, 43:31
http://www.veterinaryresearch.org/content/43/1/31RESEARCH Open AccessThe extradomain a of fibronectin enhances the
efficacy of lipopolysaccharide defective
Salmonella bacterins as vaccines in mice
Beatriz San Román1, Victoria Garrido1, Pilar-María Muñoz1,2, Laura Arribillaga3, Begoña García1, Ximena De Andrés1,
Virginia Zabaleta1, Cristina Mansilla3, Inmaculada Farrán1, Iñigo Lasa1, Damián De Andrés1, Beatriz Amorena1,
Juan-José Lasarte3 and María-Jesús Grilló1*Abstract
The Extradomain A from fibronectin (EDA) has an immunomodulatory role as fusion protein with viral and tumor
antigens, but its effect when administered with bacteria has not been assessed. Here, we investigated the adjuvant
effect of EDA in mice immunizations against Salmonella enterica subspecies enterica serovar Enteritidis (Salmonella
Enteritidis). Since lipopolysaccharide (LPS) is a major virulence factor and the LPS O-polysaccharide (O-PS) is the
immunodominant antigen in serological diagnostic tests, Salmonella mutants lacking O-PS (rough mutants)
represent an interesting approach for developing new vaccines and diagnostic tests to differentiate infected and
vaccinated animals (DIVA tests). Here, antigenic preparations (hot-saline extracts and formalin-inactivated bacterins)
from two Salmonella Enteritidis rough mutants, carrying either intact (SEΔwaaL) or deep-defective (SEΔgal)
LPS-Core, were used in combination with EDA. Biotinylated bacterins, in particular SEΔwaaL bacterin, decorated
with EDAvidin (EDA and streptavidin fusion protein) improved the protection conferred by hot-saline or bacterins
alone and prevented significantly the virulent infection at least to the levels of live attenuated rough mutants.
These findings demonstrate the adjuvant effect of EDAvidin when administered with biotinylated bacterins from
Salmonella Enteritidis lacking O-PS and the usefulness of BEDA-SEΔwaaL as non-live vaccine in the mouse model.Introduction
Fibronectin is a dimer, with monomers comprising three
types (I, II and III) of homologous repeat units [1].
Three of its alternatively spliced exons (IIIA, IIIB and
IIIC, also referred to as EDA -Extra domain A-, EDB
-Extra domain B- and III-CS) correspond to the type III
repeat unit [2]. EDA and EDB are produced in vivo in
response to tissue injury or other warning signals. Par-
ticularly, EDA is produced during embryonic develop-
ment and in rheumatoid arthritis, wound healing,
epithelial fibrosis, vascular intimae proliferation or in-
flammation in adults [3,4]. EDA induces NF-κB factor
activation, proteoglycan release, and 1, 2 and 9 metallo-
proteinase production, involved in connective tissue de-
struction following lesion development, as well as in* Correspondence: mariajesus.grillo@unavarra.es
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distribution, and reproduction in any mediummonocyte and dendritic cell migration through the basal
membrane. Such events are triggered in response to the
interaction between EDA and its specific Toll Like Re-
ceptor 4 (TLR-4), which also binds to lipopolysaccharide
(LPS) of Gram negative bacteria [5,6]. Hence, EDA has
been proposed to induce maturation of dendritic cells
through TLR-4 activation, favouring antigen uptake, ex-
pression of co-stimulatory signals, antigen presentation
and induction of anti-viral or anti-tumoral T cell
responses [6-8]. Recombinant EDA has been expressed
in E. coli and tobacco chloroplasts, maintaining its
proinflammatory properties [8]. Easy scale-up, high
safety standards and an enormous capacity to synthesize
and accumulate foreign proteins in plant chloroplasts [9]
may be advantages of using plants as production plat-
forms for biopharmaceuticals [10].
Several Salmonella live attenuated strains, including
auxotrophic, metabolic and structural (semi-rough) atte-
nuated mutants [11-15] have been proposed as effectiventral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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not safe enough in animals, may release genetically
modified microorganisms to the environment and
human food-chain, and may interfere in serological diag-
nostic tests based on the detection of antibodies against
the LPS O-Polysaccharide (O-PS) [16] and/or flagellin
[17], limiting their practical use in sanitary control cam-
paigns. Therefore, most of the currently recommended
vaccines against animal salmonellosis include bacterins
from smooth attenuated Salmonella spp. [18]. Also, bac-
terial hot-saline (HS) extracts have been proposed as safe
vaccines [19,20]. Since LPS is a major virulence factor
and the LPS O-PS is the immunodominant antigen in
serological diagnostic tests, Salmonella mutants lacking
LPS O-PS (rough mutants) represent an interesting ap-
proach for developing new live attenuated vaccines [13].
In line with this, some rough mutants such as Salmon-
ella Typhimurium ΔrfaH have been proposed as live
vaccine candidates [21,22] but others have been consid-
ered either too virulent (such as Salmonella Typhimur-
ium ΔwaaL) to be safe or too attenuated (Salmonella
Typhimurium ΔgalE or ΔwaaG mutants) to confer pro-
tection against virulent infections, being discarded as
vaccine candidates [20].
This work aims to investigate the adjuvant value of
EDA, using HS or bacterins obtained from Salmonella
Enteritidis rough mutants differing in LPS-Core com-
position (SEΔwaaL and SEΔgal) as antigenic prepara-
tions, in a sublethal challenge mouse model.
Materials and methods
Bacterial wild-type and mutant strains
Parental wild-type (SE-wt) strain Salmonella Enteritidis
3934 [23] was used as parental strain to produce rough
mutants, as smooth control strain and as virulent strain
for challenge. Mutant strain SEΔwaaL was obtained by
replacing the waaL gene with a chloramphenicol resist-
ance cassette using a one-step inactivation technique
[24] with some modifications [25]. The chloramphenicol
resistance cassette was amplified by PCR from the
MudQ transposon, using the waal-Clo Fw and waal-Clo
Rv primers described in Table 1. Mutant strain SEΔgal
was constructed by 4378 bp galETKM operon deletion
using the plasmid pKO3blue [26] and the gal-A/gal-B
and gal-C/gal-D pairs of primers (Table 1).
Characterization of rough mutants
The absence of LPS O-PS and the differences in size (i.e.
in core structure) of the LPS-Core in SEΔwaaL and
SEΔgal rough mutants were verified by SDS-PAGE silver
staining, modified for LPS identification as described
previously [27]. Surface topology was analyzed by sus-
ceptibility to 17 Salmonella Enteritidis Typing Phages
(SETPs; named from SETP 1 to 17) and Felix O1 (FO;which specifically recognizes the outer LPS-Core of
most Salmonella spp.), according to standard protocols
[28,29] of the Salmonella National Reference Laboratory
(Instituto de Salud Carlos III, Madrid, Spain). The pres-
ence of flagellum antigens was determined by direct
anti-H slide agglutination tests [18] and motility was
analyzed by the halo generated in swimming and swarm-
ing assays [30]. The outer membrane permeability of the
mutants was assessed by both the Minimal Bactericidal
Concentration to Polymyxin B using a standard microdi-
lution test [31,32] and the bactericidal effect of non-
immune human serum [33]. Other phenotypic charac-
teristics were assessed as described elsewhere [23].
Finally, virulence studies were performed in BALB/c
mice, by determining lethality and splenic infections in
surviving mice. For this, mice (n= 5) were inoculated
intraperitoneally with 2 × 103, 2 × 105 or 2 × 107 CFU/ani-
mal of SEΔwaaL or SEΔgal mutants. A group of mice
(n= 5) inoculated with 2 × 103 CFU/mouse of smooth
parental SE-wt strain was used as reference. Deaths were
recorded for 2 weeks after infection. Then, the percent-
age of cumulative survival in mice was calculated by the
Kaplan-Meier analysis, and statistically compared by the
LogRank test (see below). Moreover, the number of vi-
able bacteria was determined in spleens of surviving
mice and expressed as the mean± SD of log10 CFU/
spleen, as described previously [19].
Production and characterization of antigenic preparations
Recombinant protein EDA was obtained either in E. coli
BL21(DE3) cells (Amersham Pharmacia Biotech) or
tobacco plant chloroplasts (named MEDA) as described
previously [6,8]. After filter-sterilization in a 0.2-μm
membrane (Millipore), the absence of bacterial contami-
nants in both EDA preparations was assessed by plating
onto agar.
Bacterial antigens were obtained by HS extraction or
formalin-inactivation (bacterins) from SEΔgal (HS-SEΔ-
gal and B-SEΔgal), SEΔwaaL (HS-SEΔwaaL and B-SEΔ-
waaL) and SE-wt (HS-SEwt and B-SEwt) strains, as
described previously [19,34].
To improve binding of EDA to the bacterial cell sur-
face, a recombinant fusion protein of EDA and streptavi-
din (named EDAvidin) was obtained and mixed with
bacterins previously biotinylated to obtain the antigenic
preparations named BEDA. EDAvidin was produced
from the expression plasmid pET21a-EDA-Streptavidin
constructed with the pET21a-Streptavidin-Alive [35]
expressing wild-type subunit of streptavidin with a 6His-
tag. The DNA sequence encoding EDA was amplified by
PCR, using primers CATATGAACATTGATCGCCC
TAAAGGACT (Upper EDA-NdeI) and CATATGTGTG
GACTGGATTCCAATCAGGGG (Lower EDA-NdeI) and
the plasmid pET20b1-2 as a probe. The resulting PCR
Table 1 Oligonucleotides designed and used in this study
Oligonucleotide Sequence (5′to 3′)
waal-Clo Fw TCACCAGAACAGAACCTGGCGAAT
TTAGATGCCACAAGC
GTATTTGGAAAGATTCATTA
AGTGTAGGCTGGAGCTGCTTCa
waal-Clo Rv AGTTGGGAAAATGTAGCGCAGCG
TTTCGAGGAACAAAT
GAAAAACTGGTTTGATAAGTG
ACATATGAATATCCTCCTTAGA
galA GCGGCCGCATTCAGCCCCTGCAACG
galB CTCGAGGCCGCTACATGCCCGA
galC CTCGAGCTCCGTTAAGCCTATGGT
galD AGATCTAATCTGGTGACCGACAGA
aThe primer sequence for the chloramphenicol resistance cassette is
underlined.
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TA CloningW kit (Invitrogen LifeTechnologies). All con-
structs were verified by DNA sequencing. The resulting
plasmid expressing EDA in the C-terminus of streptavidin
was employed for transformation and expression of EDA-
vidin in E. coli BL21(DE3) cells, and the fusion protein
was purified by affinity chromatography (HisTrapTM HP
columns, GE Healthcare Life Sciences). The Sulfo-NHS-
SS-Biotin system (ThermoScientific) was used for bacterin
biotinylation, and the non-reacting Sulfo-NHS-SS-Biotin
molecules were removed by dialysis using a Slide-a-Lyzer
Dialysis cassette (3,500-MWCO, ThermoScientific). To
determine the level of free amines, bacterins B-SEΔgal, B-
SEΔwaaL and B-SEwt were labeled with carboxyfluores-
cein succinimidyl ester (CFSE) 0.125 μM (Invitrogen),
washed twice and analysed by flow cytometry. Unlabeled
SE-wt bacterins were used as negative control.
LPS was quantified by detecting 2-keto-3-deoxyocto-
nate (Kdo) corrected for 2-deoxyaldoses, as described
previously [36]. Protein and antigenic profiles of bacter-
ial and recombinant protein preparations were analysed
by Coomassie (Bio-Rad) and immunoblotting methods,
respectively. Where indicated, samples were also loaded
without boiling onto the SDS-polyacrylamide gels in
order to visualize the presence of tetramers of the EDA-
vidin fusion protein. Immunoblotting was performed
using sera from mice experimentally infected with
smooth SE-wt or from EDA hyperimmunized rabbits as
primary antibodies and horseradish anti-mouse IgG or
goat anti-rabbit IgG (ThermoFisher) as secondary anti-
bodies, and the reaction was developed with diamino-
benzidine. Proteins were quantified by the Bradford
method (Bio-Rad).
Finally, the ability of EDAvidin to bind biotinylated
and non-biotinylated bacterins was assessed by ELISA inplates coated with 0.1 μg/well of biotinylated bacterins
or conventional bacterins as control. After incubation
with 10% foetal calf serum (Invitrogen LifeTechnologies),
3 μg/mL of EDA or EDAvidin proteins were added,
incubated with anti-EDA rabbit polyclonal antibody and
anti-rabbit whole IgG horseradish peroxidase conjugated
antibody (Sigma). The final reactions were developed
with tetra-methyl-benzidine substrate (BD Biosciences),
stopped with 2 N H2SO4, and read at 450 nm in a Mul-
tiskan Ascent apparatus (ThermoElectron).
Efficacy of immunization and antibody responses
assessment
Eight to ten-week old female BALB/c mice (Charles
River International) were accommodated (Public Univer-
sity of Navarre registration code ES/31-2016-000002-
CR-SU-US) and handled in compliance with the current
European, national and local (RD 1201/2005) regula-
tions, following the FELASA and ARRIVE guidelines
and with the approval of the UPNA Animal Experimen-
tation Committee and Navarre’s Government. For
immunization, mice were inoculated intraperitoneally
(IP) with a volume of 0.1 mL of live bacteria or antigenic
preparations in PBS. Bacterial suspensions were adjusted
by spectrophotometry in PBS (O.D. at 600 nm=0.150
contains approximately 2 × 108 CFU/mL) and the exact
number of CFU in each suspension was retrospectively
assessed, by serial dilutions and plating on agar. Efficacy
was determined from at least two independent experi-
ments with statistically equivalent controls.
In a first set of experiments, a total of 30 mice (6
groups; 5 mice/group) were IP immunized with HS or
bacterin preparations (20 μg protein/mouse), alone or in
physical mix with EDA or MEDA (40 μg/mouse). A total
of 45 control mice (9 groups; 5 mice/group) were inocu-
lated with: (i) HS-SEwt or B-SEwt (20 μg protein); (ii)
PBS; or (iii) EDA or MEDA (40, 100 or 200 μg/mouse).
Four weeks later, all mice were challenged IP with the
optimal sub-lethal dose of around 2.5 × 102 CFU SE-wt
and, 4 days later, the mean (n= 5) number of log10 CFU/
spleen challenging strain was determined [37]. The opti-
mal sub-lethal dose (i.e., the minimal dose able to induce
moderate and homogeneous levels of splenic infection in
all mice) was estimated in a previous dose–response ex-
periment, where mice (n= 5) were IP inoculated with 50,
100, 250, 500 or 1000 CFU/mouse, and log10 CFU/
spleen determined 4 days later.
A similar immunization-challenge murine model (but
using 4 mice/group) was applied in a second set of experi-
ments, to determine the efficacy of biotinylated bacterins
(20 μg/mouse) bound to EDAvidin (75 μg/mouse) (i.e.
BEDA-SEΔwaaL and BEDA-SEΔgal, respectively). Besides
the above-mentioned controls, live SEΔwaaL or SEΔgal
live mutants (1× 104 CFU/animal, IP) were included.
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period was distinguished from that of SE-wt challenging
strain by double plating in agar and agar supplemented
with chloramphenicol (20 mg/L). Persistence of SEΔgal
was not determined since this mutant was cleared from
spleens within 2 weeks post-inoculation, as verified in the
virulence assay (Additional file 1: Table S1).
Just before challenge, mice sera were analysed for Sal-
monella specific immunoglobulin (IgG + IgM and IgG2a/
IgG1) quantification by indirect ELISA, using HS
extracts (HS-SEwt for IgG+ IgM or homologous HS ex-
tract for IgG2a/IgG1 isotype determination) as coating
antigens and horseradish anti-mouse IgG and IgM
(H+L) (InmunoPure, Pierce) or anti-mouse IgG1 or
IgG2a (Nordic Immunological) as conjugates. Positive
control sera from mice experimentally infected with SE-
wt, and negative control sera from animals inoculated
with PBS were included in each ELISA plate. Serum titre
was defined as the reciprocal of the highest serum dilu-
tion showing a mean O.D. value equal to or higher than
that of the negative control sera (n= 4) obtained from
mice inoculated with PBS, plus 3 times the SD. Titers of
IgG+ IgM were expressed as the mean and SD of indi-
vidual log10 titre obtained; and the Th1/Th2 balance, as
the mean and SD of individual log10 IgG2a/log10 IgG1
ratio [38].
Statistical analysis
Kolmogorov-Smirnov test was first applied to assess the
normal distribution of data. Then, means were statisti-
cally compared by a one-way ANOVA test, followed by
the Fisher’s Protected Least Significant Difference
(PLSD) test (when four or less groups were compared)
or Bonferroni’s test (when more than four groups were
compared). Efficacy was determined, from at least two
independent experiments with statistically equivalent
controls, by statistical comparison of the mean (n= 5)
log10 SE-wt CFU/spleen obtained in immunized vs. con-
trol mice. In mice survival assays, the percentage of cu-
mulative survival was calculated by the Kaplan-Meier
analysis, and statistically compared by the LogRank
(Mantel-Cox) test.
Results
Characterization of SEΔwaaL and SEΔgal LPS O-PS
deficient mutants
LPS SDS-PAGE silver stain showed that both rough
mutants had an O-PS free LPS, but SEΔgal had a LPS-
Core smaller than that of SEΔwaaL (Figure 1a), as
expected from the mutant design. This difference in LPS-
Core size was in agreement with the results obtained in
the phage susceptibility assay (Figure 1b), where in con-
trast to SE-wt, both mutants were resistant to phages that
recognize specifically O-PS epitopes (i.e. SETPs 1, 3, 5, 7,8, and 10–16) belonging to Podoviridae and Siphoviridae
morphotypes [29], but only SEΔwaaL retained susceptibil-
ity to the Myoviridae (i.e. SETPs 2, 4, 9), SETP17 and FO
phages that recognize specifically the external LPS-Core
epitopes, indicating that this mutant had an intact LPS-
Core whereas SEΔgal had a more pronounced defect.
Anti-H agglutination indicated that both rough mutants
had flagellum antigens. Phenotypic differences in motility
and biofilm formation were observed between both rough
mutants and with respect to the parental strain SE-wt
(Figure 1c). Specifically, the SEΔgal mutant retained par-
tially the flagellum motility, as indicated by the swimming
and swarming halos observed, but showed a cellulose pro-
duction deficiency in the calcofluor binding assay, and also
a diminished biofilm formation either in rich LB or in nu-
trient deficient ATM media (Figure 1c). In contrast, the
SEΔwaaL mutant lacked motility, but maintained the cap-
ability of its parental strain to retain the cellulose on the
cell surface and, consequently, to form biofilm in the
ATM stirring assay (Figure 1c). Susceptibility to Poly-
myxin B (Additional file 2: Figure S1-a) showed that the
SEΔgal mutant was more susceptible (0.125 μg/mL) to
cationic peptides than both SEΔwaaL (0.250 μg/mL) and
SE-wt (4 μg/mL) strains. Moreover, susceptibility to non-
immune serum revealed a drastic reduction in the number
of surviving bacteria in both rough mutants compared to
strain SE-wt, more marked in SEΔgal (Additional file 2:
Figure S1-b). In fact, few colonies of SEΔgal (83 CFU) or
SEΔwaaL (325 CFU) per million of bacteria resisted the
bactericidal effect of serum complement, whereas around
5× 104 CFU SE-wt were resistant.
Finally, virulence was measured by the ability of bacteria
to induce lethality in the infected mice (Additional file 1:
Table S1). As expected, all mice inoculated with
2× 103 CFU of the strain SE-wt died (at day four) after in-
oculation. However, none (SEΔgal) or only one (SEΔ-
waaL) of the mice inoculated with this dose succumbed at
the end of the experiment (2 weeks post-inoculation), in-
dicating that both rough mutants were less (p=0.0027 in
LogRank test) virulent than the smooth parental strain
SE-wt. Virulence differences were also observed between
both rough mutants, since all mice infected with SEΔgal,
at any dose, survived to the end of the experimental period
without signs of pain or illness, while those inoculated
with SEΔwaaL showed increased (p=0.035) lethality in
cumulative survival analysis when infected at the highest
dose, either at day 5 (all the mice inoculated with
2× 107 CFU/mouse died) or at day 12 (50% of cumulative
survival in animals inoculated with 2 × 105 CFU/mouse)
(Additional file 1: Table S1). Similarly, highly significant (p
< 0.005) differences between both rough mutants were
observed in the levels of splenic infections found in surviv-
ing mice (Additional file 1: Table S1), irrespectively of the
infection dose used. Mice inoculated with 2 × 103 or
CA
B
Figure 1 Phenotypic characterization of Salmonella Enteritidis SEΔwaaL and SEΔgal mutants compared to SE-wt parental strain. (A)
SDS-PAGE with alkaline silver staining of LPS; (B) phage susceptibility to the 17 Salmonella Enteritidis Typing Phage collection (named from 1 to
17) and FO bacteriophages; and (C) CF: Calcofluor; CR: Congo Red; LB, biofilm formation in static LB rich medium; ATM, biofilm formation in
stirring ATM nutrient deficient medium; swimming; and swarming assays.
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log CFU/spleen, respectively) cleared from infection at
week 2, and those infected at a high dose (2× 107 CFU)
were only moderately infected (3.6 mean log CFU). Finally,
all surviving mice infected with 2 × 103 or 2 × 105 CFU of
SEΔwaaL retained more than 4.4 mean log CFU in spleen.1     2   3     4     5 6 7 8    9 10
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Figure 2 SDS-PAGE electrophoretic profiles of bacterial
proteins from HS and bacterins (Panel A) and EDA based
recombinant proteins (Panel B). (A) Coomassie blue (lanes 1–7)
and Western-Blot of bacterins using anti-Salmonella mouse serum
(lanes 8–10). Lane 1: molecular weight marker; lanes 2–4: HS extracts
from SE-wt, SEΔwaaL and SEΔgal, respectively; lanes 5–7: bacterins
from SE-wt, SEΔwaaL and SEΔgal, respectively; lanes 8–10: bacterins
from SE-wt, SEΔwaaL and SEΔgal, respectively; and (B) Coomassie
blue of EDAvidin denatured by boiling (lane 2) or native (lane 3).
Lane 1: molecular weight marker.Characterization of antigen preparations and
enhancement of EDA binding to antigen
The results on protein quantification revealed that HS
from rough strains showed an enriched content (20–22%
approximately) in comparison with HS-SEwt (around
12%), whereas bacterins from both wild-type and rough
strains had a similar protein content (1.1–1.2 mg/mL).
The LPS Kdo content was 0.8%, 1.1% and 1.6% in HS-
SEΔwaaL, HS-SEΔgal and HS-SEwt, respectively. Coo-
massie and Western-Blot electrophoretic profiles of pro-
teins indicated that HS extracts from rough and wild-type
strains displayed similar profiles, including bands of 17
and 21 KDa fimbrial antigens, different porins, and 35–40
KDa outer membrane proteins (Figure 2a). However, bac-
terins showed a protein spectrum wider than that of HS
extracts, including those of high (above 40 KDa, such as
55 KDa flagellin) and low (below 20 KDa) molecular
weights, likely eliminated from HS extracts by boiling,
autoclaving and/or dialysis (Figure 2a).
According to SDS-PAGE and Western-Blot with anti-
His or anti-EDA antibodies, purified EDA and MEDArecombinant proteins had the expected molecular
weights (13 and 16 KDa, respectively) [8,39]. Regarding
EDAvidin, a 24 KDa band was observed in SDS-PAGE
gels (Figure 2b). However, native (unboiled) EDAvidin
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form (between 100 and 150 KDa).
In order to enhance the binding of EDA to the bacter-
ial antigens, we determined if the capacity of EDA to
bind the bacterial cell surface was increased when using
EDAvidin and biotinylated bacteria (Figure 3). The
results of the ELISA (performed with wells coated with
biotinylated or non-biotinylated bacterins) indicated that
EDAvidin but not free EDA bound biotinylated bacter-
ins, with increased affinity for biotinylated BEDA-SEΔgal
compared to BEDA-SEΔwaaL (Figure 3).
Since the biotinylation process involves the binding of
Sulfo-NHS-LC biotin to free amines on the bacterial
wall, the decreased binding of bacterin SEΔwaaL mutant
to EDAvidin with respect to SEΔgal or SE-wt could be
related to a decreased level of biotinylation of this mu-
tant. The flow cytometry results after CFSE labelling
(Additional file 3: Figure S2) revealed that bacterin SEΔ-
waaL had a significantly weaker labeling compared to
SEΔgal or SE-wt, in agreement with the results of Fig-
ure 3 and the hypothesis proposed.EDA/MEDA increases the efficacy of bacterins obtained
from LPS O-PS deficient antigens
Mice (n= 5) inoculated with increasing doses (40, 100 or
200 μg/mouse) of EDA or MEDA alone did not show ei-
ther pain signs after inoculation of these compounds or
unspecific protection after challenge with SE-wt strain
infection, reaching then infection levels of around 7 logFigure 3 EDAvidin binding to biotinylated bacterins in ELISA.
ELISA plates coated with biotinylated (Biot) or not biotinylated
control (B-SEΔwaaL, B-SEΔgal and B-SEwt) bacterins were incubated
with EDAvidin or EDA alone (control). Binding was monitored using
a rabbit anti-EDA polyclonal antibody and an anti-rabbit whole IgG
horseradish-peroxidase-conjugated second antibody. The O.D. values
at 405 nm (mean± SD) are represented.CFU/spleen, similar to those reached in unvaccinated
controls (Figure 4). Moreover, none of the animals sub-
mitted to vaccination in this work presented signs of
pain or discomfort and all of them survived up to the
end of the experimental period, including those immu-
nized with live mutants.
In the dose–response assay with the virulent strain SE-
wt, mice inoculated with 50 or 100 CFU showed inconsist-
ent infections and those inoculated with 500 or 1000 CFU
showed saturating infections (Additional file 4: Table S2)
with signs of septic shock close to death. In consequence,
2.5 × 102 CFU/mouse was chosen as the optimal sub-lethal
dose of challenge in the efficacy experiments.
The effect of EDA on protection was studied in mice
(n= 5) immunized with HS or bacterins from isogenic
rough mutants administered in a simple physical mix
with EDA (HS and bacterins) or MEDA (only bacterins)
and challenged 4 weeks later with a sublethal dose of
SE-wt. In the absence of EDA/ MEDA, vaccination with
HS-SEwt or B-SEwt (positive controls of protection) pre-
vented virulent infection, whereas mice unvaccinated
(PBS control group) reached around 7 log CFU/spleen
(Figure 4). Immunization with HS-SEΔwaaL, HS-SEΔgal
or B-SEΔgal did not prevent the virulent infection,
reaching a mean log CFU of SE-wt in spleen statistically
equivalent to that of the PBS control group (Figure 4).
In contrast, B-SEΔwaaL alone conferred significant pro-
tection (P= 0.001 vs. PBS control), superior to that con-
ferred by B-SEΔgal (P< 0.0001 between both mutants).
The combined administration of EDA in preparations
with rough HS extracts did not improve protection sig-
nificantly compared to administration of these antigens
alone. Finally, when using bacterins, EDA and MEDA
improved significantly (P< 0.001) the protection con-
ferred by B-SEΔgal (Figure 4b) but not or only moder-
ately that conferred by B-SEΔwaaL (Figure 4a).
Increased binding of EDA to the antigen enhances
protection and antibody production
In order to determine whether a strong binding of EDA
to the surface of bacterins might improve immunogen-
icity, biotinylated bacterins mixed with the EDAvidin
(giving rise to the BEDA bacterins) were used for
immunization, using live rough mutants as reference. All
mice were challenged with the SE-wt strain at week 4
after immunization and the number of SE-wt and SEΔ-
waaL determined in spleen 4 days later. Mice vaccinated
with the rough mutants were found less (P< 0.05) pro-
tected than those immunized with B-SEwt (positive con-
trols). Mice immunized with SEΔwaaL mutant retained
3.85 ± 0.21 log10 CFU of the mutant in their spleens, re-
vealing the persistence of this mutant throughout the ex-
perimental period, with infection levels similar to those
observed by this mutant at week 2 (Additional file 1:
A B
Figure 4 Protection conferred by antigenic preparations from Salmonella Enteritidis rough mutants in BALB/c mice. Immunizations. (A)
SEΔwaaL immunizations; and (B) SEΔgal immunizations. Mice were immunized IP with hot saline (HS) extracts (HS-SEΔwaaL and HS-SEΔgal; grey
boxes), formalin inactivated bacterins (B-SEΔwaaL and B-SEΔgal; grey line boxes), alone, in combination with EDA (+EDA) or MEDA (+MEDA), or
as biotinylated bacterins bound to EDAvidin (BEDA-SEΔwaaL and BEDA-SEΔgal; white boxes). Control groups of mice (n = 4) received live rough
mutants (SEΔwaaL or SEΔgal, vertical line boxes), either HS or bacterin obtained from Salmonella Enteritidis parental strain (represented as B-
SEwt; black boxes) or PBS (black boxes). Four weeks after vaccination, all mice were challenged IP with 2.3 × 102 CFU of Salmonella Enteritidis
strain 3934 (SE-wt) per animal and the degree of protection expressed as the mean log10 CFU/spleen of SE-wt, at day 4 after challenge. Statistical
comparisons were performed by ANOVA and Fisher’s PLSD test. * P< 0.01 for differences with the corresponding bacterin administered alone, i.e.
BEDA-SEΔwaaL vs. B-SEΔwaaL; and BEDA-SEΔgal or B-SEΔgal plus EDA/MEDA vs. B-SEΔgal.
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and BEDA-SEΔgal preparations improved significantly
the levels of protection compared to the bacterin admi-
nistered either alone (P< 0.001) or mixed just with EDA
(P ≤ 0.03). Strikingly, the efficacy of BEDA-SEΔwaaL and
BEDA-SEΔgal was, respectively, similar to (P> 0.05) and
higher than (P ≤ 0.01) that conferred by the isogenic live
rough mutants. Finally, live rough mutants were less
(P< 0.05) effective than B-SEwt, whereas BEDA-SEΔ-
waaL conferred a protection statistically equivalent to
this positive control (B-SEwt), 2 out 4 mice being freeTable 2 Immunoglobulin titres (IgG plus IgM mean log
titers and IgG2a/IgG1 log ratios) in mice, measured at
week 4 after immunization with bacterins, either
physically mixed just with EDA or bound to EDA
(EDAvidin) by streptavidin-biotin (BEDA) interaction
Inoculation group Log10 IgM+ IgG Log10 IgG2a/IgG1 ratio
(mean± SD) a (mean± SD) a
SE-wt live 3.45 ± 0.17 1.18 ± 0.26
SEΔwaaL live 3.60 ± 0.73 1.21 ± 0.10
SEΔgal live 2.02 ± 0.45 1.05 ± 0.07
B-SEΔwaaL+ EDA 2.54 ± 0.38 1.05 ± 0.20
B-SEΔgal+ EDA 2.69 ± 0.42 0.85 ± 0.12
BEDA-SEΔwaaL 2.77 ± 0.51 1.45 ± 0.20
BEDA-SEΔgal 3.07 ± 0.51 0.74 ± 0.09
a Serum titre was defined as the reciprocal of the highest serum dilution
showing a mean O.D. value equal to or higher than that of the negative
control sera (n= 4) obtained from mice inoculated with PBS, plus 3 times the
SD. Mean and SD (n= 4) represent the data obtained in triplicate.from virulent infection. Therefore, the increased binding
of EDA to antigens favoured by streptavidin-biotin inter-
actions resulted in enhanced protection.
In an attempt to initiate a search for an immune cor-
relate with protection, IgG+ IgM mean titers and IgG2a/
IgG1 ratios were determined in sera obtained just before
challenge from mice immunized with bacterins, either
physically mixed just with EDA or bound to EDA by
streptavidin-biotin (BEDA) interaction. Mice immunized
with BEDA-SEΔwaaL or B-SEΔwaaL+EDA had lower
(P< 0.01) levels of IgG+ IgM than those immunized
with the live SEΔwaaL mutant (Table 2). In contrast,
BEDA-SEΔgal and B-SEΔgal+EDA preparations
induced IgG+ IgM levels higher (P< 0.05) than those
induced by the live SEΔgal mutant. The humoral
responses to BEDA-SEΔwaaL or B-SEΔwaaL+EDA
were accompanied by an enhanced Th1 response (IgG2a/
IgG1 balance between 1.45 ± 0.20 and 1.05 ± 0.20), but
this enhancement was not observed in the case of SEΔgal
preparations, which induced a response slightly biased
towards a Th2 profile (0.74 ± 0.09 and 0.85 ± 0.12 with
BEDA-SEΔgal and B-SEΔgal+EDA, respectively).
Discussion
Many live attenuated or inactivated vaccines against a
variety of pathogens such as Salmonella require booster
immunizations to attain the expected protection. Since
vaccine efficacy may increase with the use of adjuvants,
research on adjuvant performance is necessary. In this
context, the positive effect of EDA, when administered
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studied in a vaccination-challenge mouse model involv-
ing two Salmonella Enteritidis rough mutants (SEΔwaaL
and SEΔgal) differing in the LPS-Core composition.
None of these mutants produced LPS O-PS antigen,
which may help to distinguish animals vaccinated with
these mutants from those infected by field strains. The
absence of either (O-PS)-to-LPS assembly enzymes
(SEΔwaaL) or LPS-Core galactose synthesis enzymes
(SEΔgal) led to an intact (in SEΔwaaL) or a defective (in
SEΔgal) LPS-Core, according to results on SDS-PAGE
and susceptibility to SEPTs bacteriophages, as expected
from the genetic design of these mutants and previous
findings on similar mutants [20,22,40,41]. Functional
mutants in the gal operon, which includes galE, galT,
galK and galM genes, all involved in the synthesis of the
LPS-Core galactose [42], have been obtained by inactiva-
tion of the galE gene [41], but these single-gene mutants
may revert to a smooth-LPS by incorporating exogenous
precursors of galactose into the biosynthetic pathway,
both in vitro [41] and in vivo [21,43,44]. Thus, the mu-
tant production strategy applied in this work, based on
the use of a complete deletion of gal operon to produce
the SEΔgal mutant, ensured the rough phenotype of this
mutant through the blockage of galactose synthesis from
endogenous or exogenous sources [44].
When attempting the design of non-live vaccines, HS
extracts (enriched in outer membrane components) and
formalin-inactivated bacteria (bacterins that retain all
the external and internal bacterial antigens) were used
as antigens [19,37]. Differences in vaccine efficacy be-
tween studies using Salmonella Enteritidis HS extracts
in mice [19,45] could be explained by differences in bac-
terial genetic makeup, extract preparation and enrich-
ment methods or immunization vehicles. The HS
preparations obtained from the Salmonella Enteritidis
rough mutants reported here did not protect mice
against a virulent challenge, whereas mice immunized
with HS-SEwt were protected (100% mouse survival and
80% uninfected spleens), demonstrating the essential
role of the LPS O-PS in HS-driven protection. The phy-
sicochemical characterization of antigenic preparations
confirmed that bacterins had a broader protein spectrum
compared to HS extracts. This difference could be
related to differences in preparation methods (boiling,
ultracentrifugation and dialysis for HS extracts and not
bacterins). Bacterins lacking LPS O-PS may be useful
vaccines against heterologous Salmonella species and
serovars, since the rough phenotype has an enhanced
immunogenicity of minor antigens, mainly porins and
lipoproteins conserved in Salmonella serotypes [20].
Interestingly, B-SEΔwaaL induced partial protection in
mice whereas B-SEΔgal did not confer protection, indicat-
ing that a complete LPS-Core could play an essential role.Once verified that the protection obtained with HS or
bacterins from both rough mutants was below that of the
B-SEwt, the potential of EDA as immunopotentiator in
non-live bacterial vaccines was assessed. Adjuvants such
as Freund’s complete or aluminium hydroxide do not ap-
pear to improve the immune response against Salmonella
[46,47], in contrast with polymeric carriers used to adsorb
or encapsulate bacterial extracts [19,48]. Alternatively,
adjuvants interacting directly with TLRs have successfully
immunopotentiated Salmonella Enteritidis sub-cellular
fractions. Examples are polyinosinic:polycytidylic acid
[poly(I:C)] with TLR-3 [49], CpG sequences with TLR-9
[45] and bacterial LPS with TLR-4 [46,50]. Since EDA acti-
vates TLR4 favouring viral antigen presentation [6-8,39],
mice were immunized in the presence of recombinant
EDA (produced in E. coli) or MEDA (in transformed plant
chloroplast), initially as a simple physical mix with HS
extracts (EDA) or bacterins (EDA and MEDA) from Sal-
monella rough mutants.
The effect of EDA in the efficacy of immunizations
depended on the type of antigenic preparation (found in
bacterins and not HS extracts) and the mutant from which
the bacterins were prepared (B-SEΔwaaL or B-SEΔgal). No
significant adjuvant effects were observed with EDA or
MEDA treatments when B-SEΔwaaL was administered
alone (which already conferred partial protection), but both
EDA or MEDA significantly enhanced protection when
using B-SEΔgal. This suggests that the size and/or compos-
ition of LPS-Core may have affected the affinity for TLR-4
and/or may have regulated the intracellular fate of the anti-
gen in dendritic cells, as demonstrated for LPS O-PS anti-
gen [51]. Possibly, the complete (but not the incomplete)
LPS-Core antigen competes with EDA for TLR-4 recogni-
tion, so that EDA is not free to interact with this receptor.
Alternatively, EDA and MEDA may have a higher affinity
for their surface receptors when exposed in absence of the
external LPS-Core (i.e. B-SEΔgal).
In search of strategies that would help to enhance the
binding of EDA to the antigen, the novel recombinant EDA
fused to streptavidin molecule (EDAvidin) allowed a signifi-
cant binding to biotinylated bacterins. Most likely, biotiny-
lated bacterins decorated with EDAvidin enhanced the
targeting of LPS defective bacterins to TLR4 expressing
cells, modulating the entry of the antigen and/or its intra-
cellular fate and/or the persistence in dendritic cells [51] to
favour the enhancement of the efficacy of these antigenic
preparations. This is in line with the significantly improved
protection conferred by BEDA-SEΔwaaL and BEDA- SEΔ-
gal complexes compared to bacterins alone, reaching levels
similar to those obtained with the live rough mutants and,
in the case of BEDA-SEΔwaaL, the levels conferred by the
bacterin B-SEwt positive control. Irrespective of the
decreased binding of SEΔwaaL to EDAvidin (apparently
related to a lower level of biotinylation according to flow
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each individual bacterin including SEΔwaaL increased sig-
nificantly in the presence vs. absence of EDAvidin.
Altogether, these findings demonstrate that EDA in the
form of EDAvidin-biotin complexes improves the efficacy
of non-live vaccines. Like in previous work [13], increased
IgG+ IgM levels or a Th1 biased response (according to the
IgG2a/IgG1 balance) could not be correlated with the pro-
tection conferred by both BEDA preparations (BEDA-SEΔ-
waaL and BEDA-SEΔgal), even though the immune
response must have been in both cases sufficiently
enhanced to confer significant protection.
Most studies in mice designed to assess Salmonella vac-
cine efficacy use a lethal challenge model. Here, we have
used a sub-lethal dose challenge model [19] to preserve ani-
mal welfare, yielding information in line with that obtained
with the lethal challenge model, since e.g. here live SEΔ-
waaL performed better than SEΔgal, like in previous lethal
challenge reports with similar mutants [20]. At the same
time, this model allowed the detection of increased protec-
tion in mice when EDA or MEDA were administered
mixed with B-SEΔgal, and also allowed both the selection
of bacterins and not HS from both mutants as Salmonella
antigen candidates and the detection of enhanced protec-
tion with EDAvidin bound to biotinylated B-SEΔwaaL.
Although additional work should be done in different
natural hosts to determine the true innocuousness and effi-
cacy of BEDA preparations, it is clear that EDA (as
EDAvidin) improves the efficacy of rough Salmonella bac-
terins (as biotinylated bacterins) in the mouse model. The
association between EDAvidin and B-SEΔwaaL bacterin
may be considered safe and effective for use as a non-live
vaccine, conferring a high protection against virulent infec-
tion. Employing this BEDA immunization strategy with O-
PS deficient mutants may also help to distinguish (by con-
ventional anti-O-PS or new anti-EDA serological tests) be-
tween vaccinated animals and asymptomatically infected
carriers, reservoirs of zoonotic infections. Moreover, the
use of non-live vaccines avoids the presence of genetically
modified microorganisms in farm animals and their subse-
quent release to environment or food-chain, having an
added value for consumers and veterinary use.Additional files
Additional file 1: Table S1. Virulence of SEΔgal and SEΔwaaL in BALB/
c mice.
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human serum. (A) Minimal Bactericidal Concentration (MBC) to Polymyxin
B; and (B) Susceptibility to conventional human serum, with respect to
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of Polymyxin B concentration (μg/mL) at which bacteria were not
recovered (A); and log10 CFU of viable bacteria in fresh serum per million
of viable bacteria surviving in heat-inactivated serum(B). Statistical differences (P< 0.01) were found by Fisher’s PLSD test
between SE-wt and each rough mutant.
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SEΔwaaL and B-SEwt labeled with carboxyfluorescein succinimidyl ester
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